Based on this YouTube video's total view count of 123 views and industry-standard rates, the estimated total earning is $0 - $0 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.

Explore Phase I study of ABBV-383, a BCMA×CD3 bispecific antibody, in R/R myeloma with 123 views, 1 likes, and 0 comments. Experience the impact of this video content that has captured audience attention.

Ravi Vij, MD, MBA, Washington University Medical School, St. Louis, MO, briefly comments on the results of a Phase I study evaluating ABBV-383, a BCMA × CD3 bispecific antibody in patients with relapsed/refractory (R/R) multiple myeloma (NCT03933735). Prof. Vij explains that this agent eliminates the need for step-up dosing, therefore reducing the length of hospitalization. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.

Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.

Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.

Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.